Gene delivery to periosteal cells by microneedle injection
US6525030B1 · kind B1 · utility
Assignee
Inventor
Key dates
| Filing date | Jul 11, 2000 |
| Grant date | Feb 25, 2003 |
| Priority date | — |
| Expiry date | Jul 11, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Direct gene transfer of genetic material into an external or internal target cell site (“microseeding”), in optional combination with a wound treatment chamber, are particularly effective as a means of obtaining long term expression of native or non-native polypeptides in a host. A wide variety of proteins and materials can be expressed, either for secretion into the general blood and lymphatic system, or to alter the properties of the protein, for example, to not express proteins eliciting an immune response. The use of the optional wound chamber system for gene transfer to skin target sites also allows non-invasive assessment of the success of transfer by assaying for the presence of the expressed protein in wound fluid, in contrast to the prior art use of invasive techniques, such as biopsies, in order to achieve the same assessment of early expression.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.